Advertisement

Topics

With Positive Support from Early Studies Alnylam Looks to File NDA for Second RNAi Therapeutic by...

20:00 EDT 15 Apr 2018 | BioSpace

Fueled by positive Phase I and Phase I/II results from an open-label extension (OLE) study of RNAi therapeutic givosiran, as well as an ongoing Phase III trial, Cambridge, Mass.-based Alnylam said it is eying a possible New Drug Application by the end of the year.

Original Article: With Positive Support from Early Studies Alnylam Looks to File NDA for Second RNAi Therapeutic by...

NEXT ARTICLE

More From BioPortfolio on "With Positive Support from Early Studies Alnylam Looks to File NDA for Second RNAi Therapeutic by..."

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...